Sheppard, Mullin, Richter & Hampton LLP advised Genprex, Inc.
Genprex, Inc., a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, issued a $8.0 million registered direct offering of common stock.
Genprex’s common stock is listed on the Nasdaq Capital Market under the symbol “GNPX.”
The Sheppard Mullin team, led by partner Richard Friedman (Picture), included partner Stephen Cohen and associates Nazia Khan, Alexander Yarbrough, and Matthew Hayes.
Law Firms: Sheppard Mullin;
Clients: Genprex, Inc.;